BioSyent (CVE:RX) Stock Passes Above Fifty Day Moving Average – Here’s Why

Shares of BioSyent Inc. (CVE:RX) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$10.86 and traded as high as C$11.26. BioSyent shares last traded at C$11.25, with a volume of 2,351 shares trading hands.

BioSyent Stock Performance

The company has a market capitalization of C$130.39 million, a PE ratio of 18.75 and a beta of 0.93. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13. The stock’s fifty day simple moving average is C$10.86 and its 200-day simple moving average is C$9.94.

BioSyent (CVE:RX) last announced its earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C$0.13. The firm had revenue of C$8.95 million for the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. As a group, equities analysts predict that BioSyent Inc. will post 0.6944444 earnings per share for the current year.

Insider Buying and Selling

In other BioSyent news, Director Seyed Ahmad Ashrafi sold 2,320 shares of BioSyent stock in a transaction on Friday, September 20th. The shares were sold at an average price of C$10.95, for a total value of C$25,404.00. 33.65% of the stock is currently owned by company insiders.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.